EudraCT2016‐004384‐39.

Study name	A clinical trial that examines whether the treatment with the medication olaparib in combination with the chemotherapy carboplatin is more effective than treatment with a standard chemotherapy (anthracycline/ taxane‐based) against a specific type of breast cancer
Methods	Accrual: active Accrual target: – Multicentre, phase 2 RCT Trial is being conducted in Australia Blinding: open‐label study
Participants	Early invasive triple‐negative breast cancer with positive homologous recombination deficiency (HRD) status Adjuvant or neoadjuvant: neoadjuvant
Interventions	Arm 1: intervention: olioparib and carboplatin for 6 cycles Arm 2: comparator: docetaxel, doxorubicin and cyclophosphamide for 6 cycles
Outcomes	Primary Histopathological response to preoperative chemotherapy Secondary Occurrence of pathological complete response Quality of life and sexual health scores
Starting date	Planned start date: not specified Estimated completion date: not specified
Contact information	Contact: ABCSG (info@abcsg.at)
Notes	Trial registration link: clinicaltrialsregister.eu/ctr‐search/trial/2016‐004384‐39/AT Trial sponsor: Austrian Breast & Colorectal Cancer Study Group (ABCSG) Funding considerations: Astra Zeneca